

Published in final edited form as:

Nature. 2014 March 20; 507(7492): 315–322. doi:10.1038/nature12965.

Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma

The Cancer Genome Atlas Research Network

Abstract

Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. To date, no molecularly targeted agents have been approved for the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomas to provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms This paper is distributed under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike license, and the online version of the paper is freely available to all readers.

Correspondence and requests for materials should be addressed to J.N. Weinstein (jweinste@mdanderson.org), S.P. Lerner (slerner@bcm.edu) or D.J. Kwiatkowski (dkwiatkowski@rics.bwh.harvard.edu).

The authors declare no competing financial interests.

Author Information The primary and processed data used to generate the analyses presented here can be downloaded by registered users from The Cancer Genome Atlas (<https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp>, <https://cghub.ucsc.edu/> and https://tcga-data.nci.nih.gov/docs/publications/blca_2013/). Reprints and permissions information are available at www.nature.com/reprints. Readers are welcome to comment on the online version of the paper.

The primary and processed data used to generate the analyses presented here can be downloaded by registered users from The Cancer Genome Atlas <https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp>. All of the primary sequence files are deposited in CGHub and all other data are deposited at the Data Coordinating Center (DCC) for public access (<http://cancergenome.nih.gov/>), <https://cghub.ucsc.edu/> and https://tcga-data.nci.nih.gov/docs/publications/blca_2013/. Reprints and permissions information is available at www.nature.com/reprints.

Author Contributions: The Cancer Genome Atlas research network contributed collectively to this study. Biospecimens were provided by the tissue source sites and processed by the Biospecimen Core Resource. Data generation and analyses were performed by the genome-sequencing centers, cancer genome-characterization centers and genome data analysis centers. All data were released through the Data Coordinating Center. Project activities were coordinated by the NCI and NHGRI project teams. We also acknowledge the following TCGA investigators of the Bladder Analysis Working Group who contributed substantially to the project

Project Leaders: John N. Weinstein, Seth P. Lerner

Data Coordinator: Chad J. Creighton

Analysis Coordinator: Rehan Akbani, Jaegil Kim

Manuscript Coordinator: Margaret B. Morgan

Project Coordinator: Margi Sheth

Writing Team: John N. Weinstein, David J. Kwiatkowski, Seth P. Lerner, Chad J. Creighton, Peter W. Laird, Raju Kucherlapati, Rehan Akbani, Xiaoping Su, Katherine A. Hoadley, Michael C. Ryan

Clinical Expertise: Seth Lerner, David J. Kwiatkowski, Jonathan E. Rosenberg, Dean Bajorin

Pathology Review: Hikmat Al-Ahmadie, Bogdan A. Czerniak, Donna Hansel, Victor Reuter, Brian Robinson

DNA Sequence and Copy Number Analysis: Jaegil Kim, David J. Kwiatkowski, Andrew D. Cherniack

DNA methylation analysis: Peter W. Laird, Toshinori Hinoue

mRNA analysis: Katherine A. Hoadley, William Y. Kim, Jeffrey S. Damrauer, Wei Zhang, Yuexin Liu, Rehan Akbani

microRNA analysis: Gordon Robertson, Andy J. Mungall

Transcript; Splicing analysis: Michael Ryan, John Weinstein

Protein Analysis: Rehan Akbani, Gordon B. Mills

APOBEC: Dmitry Gordenin

Pathway/Integrated Analysis: Chad J. Creighton, Nikolaus Schultz, Josh Stuart

Chromosomal rearrangements and viral integration: Xiaoping Su, Raju Kucherlapati

Batch Effects: Rehan Akbani, John N. Weinstein

Manuscript Review: Richard Gibbs 3,6, Chris Gunter(63), Matthew Meyerson 9,10

Contact PIs: John N. Weinstein, Seth P. Lerner, David J. Kwiatkowski

cycle regulation, chromatin regulation, and kinase signaling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in miRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating FGFR3-TACC3 fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the PI3K/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any common cancer studied to date, suggesting the future possibility of targeted therapy for chromatin abnormalities.

Introduction

Urothelial carcinoma of the bladder is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year¹. Previous studies have identified multiple regions of somatic copy number alteration, including amplification of *PPARG*, *E2F3*, *EGFR*, *CCND1* and *MDM2*, as well as loss of *CDKN2A* and *RBI*^{2,3}. Sequencing of candidate pathways has identified recurrent mutations in *TP53*, *FGFR3*, *PIK3CA*, *TSC1*, *RBI* and *HRAS*^{2,3}. More recently, a candidate gene study identified mutations at >10% frequency in several chromatin remodeling genes: *KDM6A*, *CREBBP*, *EP300*, and *ARID1A*⁴. Focused molecular analyses^{5,6} have delineated tumour subtypes and identified kinase-activating FGFR3 gene fusions^{7,8}.

We report here a comprehensive, integrated study of 131 high-grade muscle-invasive urothelial bladder carcinomas as part of The Cancer Genome Atlas (TCGA) project. Included are data on DNA copy number, somatic mutation, mRNA and microRNA expression, protein and phosphorylated protein expression, DNA methylation, transcript splice variation, gene fusion, viral integration, pathway perturbation, clinical correlates and histopathology to characterize the molecular landscape of urothelial carcinoma. This study identifies a number of mutations and regions of copy number variation that involve genes not previously reported as altered in a significant fraction of bladder cancers. It also identifies potential therapeutic targets in most of the samples analyzed.

Results

Demographic, clinical and pathological data

Samples, (from 19 tissue source sites), consisted of 131 chemotherapy-naïve, muscle-invasive, high-grade urothelial tumours (T2-T4a, Nx, Mx), as well as peripheral blood (n=118) and/or tumour-adjacent, histologically normal-appearing bladder tissue (n=23). Cases were retained only if they met the following criteria: tumour nuclei constituted $\geq 60\%$ of all nuclei, tumour necrosis was $\leq 20\%$ of the specimen, and variant histologies (squamous or small cell) were $\leq 50\%$ (Supplementary Text S1). Clinical and demographic characteristics are described in Supplementary Data File S1.1. Five expert genitourinary pathologists re-reviewed all of the cases for multiple parameters, including the extent of variant histology (Supplementary Text S1 and Fig. S1.1a).

Somatic DNA alterations

The tumours displayed a large number of DNA alterations, slightly fewer than in lung cancer and melanoma, but more than in other adult malignancies studied by TCGA (Fig. 1)⁹. On average, there were 302 exonic mutations, 204 segmental alterations in genomic copy number and 22 genomic rearrangements per sample. We analyzed somatic copy number

alterations (SCNAs) using both SNP 6.0 arrays and low-pass whole genome sequencing; the two were strongly concordant (Supplementary Methods S6.1 and Supplementary Fig. S6.1). There were 22 significant arm-level copy number changes (Supplementary Data File S6.1.1), and GISTIC (Supplementary Methods S6.2) identified 27 amplified and 30 deleted recurrent focal SCNAs (Supplementary Data Files S6.2.1 and S6.3.1). Focal amplifications involved genes previously reported to be altered in bladder cancer (Fig. 1c, Supplementary Fig. S6.2.1) and some not previously implicated. The latter included *PVRL4*, *BCL2L1* and *ZNF703*. The most common recurrent focal deletion, seen in 47% of samples, contained *CDKN2A* (9p21.3) and correlated with reduced expression (Fig. 1 and Supplementary Fig. S2.7). Other focal deletions containing <10 genes appeared to target *PDE4D*, *RBI*, *FHIT*, *CREBBP*, *IKZF2*, *FOXQ1*, *FAM190A*, *LRP1B* and *WWOX*.

Whole-exome sequencing of 130 tumours and matched normal samples targeted 186,260 exons in 18,091 genes (mean coverage 100×, with 82% of target bases covered >30×). MuTect¹⁰ identified 39,312 somatic mutations (including 38,012 point mutations and 1,138 indels), yielding mean and median somatic mutation rates of 7.7 and 5.5 per megabase (Mb), respectively (Fig. 1a, Supplementary Table S2.1.1). Thirty-two genes showed statistically significant levels of recurrent somatic mutation (Fig. 1b, Supplementary Table S2.1.2) by analysis using MutSig 1.5¹¹ (Supplementary Methods S2.2). Three other genes identified by MutSig were not considered further because of low or undetectable expression (Supplementary Fig. S2.1.1). A similar analysis considering only mutations in the COSMIC database² identified three more significantly mutated genes (SMGs): *ERBB2*, *ATM* and *CTNNB1* (Supplementary Table S2.1.3). We validated the mutation findings in three ways: targeted re-sequencing of all SMG mutations, comparison with RNA-Seq data for 123 samples and comparison with whole genome sequence data for 18 samples. Overall, the validation rate was > 99% by a combination of the methods (Supplemental Methods S2.4.)

Nearly half (49%) of the samples had *TP53* mutations (Fig. 1b), which were mutually exclusive in their relationship with amplification (9%) and overexpression (29%) of *MDM2*; hence, TP53 function was inactivated in 76% of samples. Most *RBI* mutations were inactivating, were associated with significantly reduced mRNA level (Supplementary Fig. S2.7) and were mutually exclusive with *CDKN2A* deletions (Supplementary Fig. S2.8 and Table S2.8.1). *FGFR3* mutations (12%) typically affected known kinase-activating sites. *PIK3CA* mutations were relatively common (20%), clustering in the helical domain near E545 (Supplementary Fig. S2.4). Most *TSC1* mutations (8%) were truncating, and six were homozygous (allele fraction > 0.5).

Many of the 32 genes identified in Fig. 1b have not previously been reported as statistically significantly mutated in bladder cancer: *MLL2* (27%), *CDKN1A** (14%), *ERCC2** (12%), *STAG2* (11%), *RXRA** (9%), *ELF3** (8%), *NFE2L2* (8%), *KLF5** (8%), *TXNIP* (7%), *FOXQ1** (5%), *RHOB** (5%), *FOXA1* (5%), *PAIP1** (5%), *BTG2** (5%), *ZFP36L1* (5%), *RHOA* (4%) and *CCND3* (4%). The nine genes marked with asterisks have not been reported as SMGs in any other TCGA cancer type or reported in another study as mutated at >3% frequency². *CDKN1A* (*p21^{CIP1}*), a cyclin-dependent kinase inhibitor¹², had predominantly null or truncating mutations, implying loss of function. Fifteen of 16 mutations in *ERCC2*, a nucleotide excision repair gene¹³, were deleterious missense mutations, suggesting dominant negative effects. *ERCC2*-mutant tumours also had significantly fewer C>G mutations than did *ERCC2*-wild type tumours (Supplementary Figs. S2.3.1 and S2.3.2), and they trended toward higher overall mutation rate (Supplementary Figure S2.12). Seven of 12 mutations in *RXRA* (retinoid × nuclear receptor alpha)¹⁴ occurred at the same amino acid (five S427F; two S427Y) in the ligand-binding domain. Those seven tumours showed increased expression of genes involved in

adipogenesis and lipid metabolism (Supplementary Fig. S2.6 and Data Files S2.6.1- S2.6.3), suggesting that the mutations cause constitutive activation.

Eleven tumours (8%) had deleterious missense mutations in the Neh2 domain of *NFE2L2*, a transcription factor that regulates the anti-oxidant program in response to oxidative stress¹⁵. Those tumours showed dramatically increased expression of genes involved in genotoxic metabolism and the reactive oxygen species (ROS) response (Supplementary Figs. S2.5.1- S2.5.3 and Data File S2.5.2). Furthermore, nine samples had mutations in redox regulator *TXNIP*¹⁶ (5 of them inactivating) and were mutually exclusive of samples with *NFE2L2* mutations, providing another mechanism for dysregulation of redox metabolism. Predominant inactivating mutations were seen in *STAG2*, an X-linked cohesin complex component required for separation of sister chromatids during cell division¹⁷ (Supplementary Fig. S2.4).

Unsupervised clustering by non-negative matrix factorization of mutations and focal SCNAs in 125 samples identified three distinct groups (Fig. 1a, Supplementary Fig. S2.1.2). Group A (red), labeled as ‘focally-amplified’, is highly enriched in focal SCNAs in several genes, as well as mutations in *MLL2* (Fig. 1; Supplementary Tables S2.1.4 and S2.1.5). Group B (blue), labeled as ‘papillary *CDKN2A*-deficient *FGFR3*-mutant’, is enriched in papillary histology. Nearly all Group B samples show loss of *CDKN2A*, and the majority have one or more alterations in *FGFR3*. Group C (green), labeled as ‘*TP53*/cell-cycle-mutant’, shows *TP53* mutations in nearly all samples, as well as enrichment with *RB1* mutations and amplifications of *E2F3* and *CCNE1* (Fig. 1, Supplementary Table S2.1.4). Those differences in pattern of mutation suggest the possibility of different oncogenic mechanisms.

Seventy-two per cent of the cancers in this study were from current or past smokers, consistent with extensive epidemiological studies indicating an association between smoking and urothelial cancer risk. In contrast with lung cancer, however, there was no statistically significant association between smoking status and the mutational spectrum, frequency of mutation in any SMG, focal SCNAs or expression subtype (Supplementary Tables S2.9.1 and S2.9.2). Never-smokers did have a slightly higher fraction of C>G mutations than did current/former smokers (28.5% vs. 23.8%, $p = 0.032$; Supplementary Figs. 2.3.2 and 2.3.3). However, unsupervised clustering of promoter CpG island DNA methylation data revealed a major subgroup (34%) of tumours characterized by cancer-specific DNA hypermethylation (CIMP) (Supplementary Fig.S7.1). Multivariate regression analysis with age, sex and tumour stage as covariates identified smoking pack-years as the only significant predictor of CIMP phenotype, as has also been reported for colorectal cancer¹⁸.

Fifty-one per cent of mutations overall were Tp*C->(T/G) (Supplementary Table S2.1.1), a class of mutation recently reported to be mediated by one of the DNA cytosine deaminases, *APOBEC19,20*. *APOBEC3B* was expressed at high levels in all of the tumours, suggesting a major role for APOBEC-mediated mutagenesis in bladder carcinogenesis (Supplementary Figs. S12.1 and S12.2).

Four genes involved in epigenetic regulation were SMGs: *MLL2*, *ARID1A*, *KDM6A* and *EP300* (Fig. 1). Truncating mutations were significantly enriched in each of those genes (Supplementary Fig. S2.2 and Data Files S2.2.1-2). Three of them had previously been identified as mutated in urothelial cancers⁴, but mutation of *MLL2*, which encodes a histone H3 lysine 4 (H3K4) methyltransferase, is a novel finding. Several other chromatin-regulating genes had mutation rates $\geq 10\%$ but were not statistically significant by MutSig analysis: *MLL3*, *MLL*, *CREBBP*, *CHD7* and *SRCAP*. Many other epigenetic regulators were mutated at lower frequency but were also enriched with truncating mutations, suggesting functional significance (Supplementary Fig. S2.2 and Data Files S2.2.1 and S2.2.2). Non-

silent mutations in chromatin regulatory genes overall were significantly enriched in bladder cancer in comparison with the entire exome, in contrast with all other epithelial cancers studied to date in the TCGA project (Supplementary Table S2.10). Mutations in *MLL2* and *KDM6A* (the latter encoding a histone H3 lysine 27 (H3K27) demethylase) were mutually exclusive (Supplementary Fig. S2.8 and Table S2.8.1), suggesting that mutations in the two genes have redundant downstream effects on carcinogenesis or that the combined loss is synthetically lethal.

Chromosomal rearrangements and viral integration

To identify structural variations and pathogen sequences, we used low-pass, paired-end, whole-genome sequencing (WGS; 6–8× coverage) of 114 tumours and RNA sequencing of all tumours. We detected 2,529 structural aberrations, including 1,153 that involve gene-gene fusions. Among the translocations, 379 were inter-chromosomal, 237 were intra-chromosomal, 274 were the result of inversions and 263 resulted from deletions (Supplementary Table S3.1). We found several recurrent translocations of likely pathogenic significance, including an intra-chromosomal translocation on chromosome 4 involving *FGFR3* and *TACC3* (n=3). The breakpoints were in intron 16 (2 cases) or exon 17 (1 case) of *FGFR3* and intron 10 of *TACC3* (confirmed by DNA sequencing and RNA-seq). All three lead to fusion mRNA products whose predicted proteins include the N-terminal 758 amino acids of FGFR3 fused with the C-terminal 191 amino acids of TACC3 (Fig. 2a). Based on the structure of the FGFR3-TACC3 fusion protein, we predict that it can auto-dimerize, leading to constitutive activation of the kinase domain of FGFR3. FGFR3-TACC3 fusion, which was recently described in both glioblastoma²¹ and bladder cancer^{7,8}, represents a promising therapeutic target. The *ERBB2* gene was also involved in translocations in four tumours, all with different fusion partners and all confirmed by DNA sequencing, RNA-Seq or both. In one case, exons 4 to 29 of *ERBB2* were fused to the promoter plus exon 1 of *DIP2B*, and the fusion product was amplified (Fig. 2b). Two other fusion products resulted in novel mRNA products whose biological significance is not known.

We identified viral DNAs in 7 of 122 tumours (6%), and viral transcripts in 5 of 122 (4%). Three tumours expressed cytomegalovirus (CMV) transcripts (encoding RL5A, RNA2.7, RL9A, RNA1.2, UL5 and UL22A), one expressed BK polyoma virus and one expressed human papilloma virus 16 (HPV16). HPV16 and human herpes virus 6B DNA were each identified in one other sample but without expression. None of the tumours expressing CMV showed evidence of CMV integration into the host genome, suggesting the presence of a stable episome. In the BK-positive tumour, two BK genes were integrated into GRB14, a signaling adapter protein for receptor tyrosine kinases. In the HPV 16-expressing case, the virus integrated into *BCL2L1*, an apoptosis-regulating gene (Fig. 2c). In that tumour, *BCL2L1* was amplified (~6×) and overexpressed (~10× median; > 2× any of the other samples). Overall, those findings suggest that viral infection may play a role in the development of a small percentage of urothelial carcinomas.

mRNA, microRNA and protein expression

Analysis of RNA-seq data from 129 tumours identified four clusters (clusters I–IV) (Fig. 3 and Supplementary Fig. S4.1). Cluster I (‘papillary-like’) is enriched in tumours with papillary morphology (p=0.0002), *FGFR3* mutations (p=0.0007, q=0.02), *FGFR3* copy number gain (p=0.04, q=0.1) and elevated FGFR3 expression (p<0.0001) (Fig. 3a). It includes all three samples with *FGFR3-TACC3* fusions. Cluster I samples also show significantly lower expression of miR-99a and miR-100, microRNAs that down-regulate *FGFR3* expression (p=0.0002, Figs. 3a S5.3)²². They also show lower expression of miR-145 and miR-125b, which have been reported as frequently downregulated in bladder

cancer²³. Tumours with *FGFR3* alterations, and perhaps other tumours that share the Cluster I expression profile, may respond to inhibitors of FGFR or its downstream targets.

Reverse-phase protein array (RPPA) data indicate that clusters I and II express high HER2 (ERBB2) levels and an elevated estrogen receptor beta (ESR1) signaling signature, indicating potential targets for hormone therapies such as tamoxifen or raloxifene (Fig. 3d). In fact, the HER2 protein levels in a subset of the tumours are comparable to those found in TCGA HER2-positive breast cancers²³.

For comparison, we asked whether any of the four clusters show gene signatures similar to those identified in any other tumour type(s) among the first 11 analyzed by TCGA. We found that the signature of bladder cancer cluster III ('basal/squamous-like') is similar to that of basal-like breast cancers, as well as squamous cell cancers of the head and neck and lung (Supplementary Fig. S4.2)^{24,25}. All four of those cancer types express characteristic epithelial lineage genes, including *KRT14*, *KRT5*, *KRT6* and *EGFR*. Basal-like subtype²⁶ and squamous cell subtype²⁷ of urothelial carcinoma, have been independently reported. Many of the samples in bladder cluster III express cytokeratins (i.e. *KRT14* and *KRT5*) that were recently reported to mark stem/progenitor cells²⁶. Some of those samples also show a level of variant squamous histology (Fig. 3b). Bladder clusters I and II show features similar to those of Luminal A breast cancer, with high mRNA and protein expression of luminal breast differentiation markers, including GATA3 and FOXA1 (Fig. 3c). Markers of urothelial differentiation such as the uroplakins are also highly expressed in clusters I and II, as are the epithelial marker E-cadherin and members of the miR-200 family of microRNAs (which target multiple regulators of epithelial-mesenchymal transition)²⁸ (Fig. 3c). Taken together, those observations suggest that, despite their diverse tissue origins, some bladder, breast, head and neck and lung cancers share common pathways of tumour development.

To determine if the expression-based clusters could be seen in other datasets, we used the muscle-invasive bladder cancer samples from Sjodahl, et al.²⁷, hierarchically clustering them with the genes used in our analysis. From the sample dendrogram, we identified four groups (Supplemental Figure S4.3a). The four groups identified in the Sjodahl data set correlated well with the four clusters identified in our TCGA data. (Supplemental Figure S4.3b).

When we analyzed the RNA-seq data for transcript splice variation using SpliceSeq²⁹ (Supplemental Material S11), one finding of interest was an average of 3% *PKM1* and 97% *PKM2* transcripts in the tumour samples. The *PKM2* isoform of pyruvate kinase is the principal driver of a shift to aerobic glycolysis in tumours (the Warburg effect)³⁰. Therefore, urothelial bladder cancers (and other cancer types) may prove sensitive to inhibition of glycolysis or related metabolic pathways.

Pathway analysis and therapeutic targeting

Integrated analysis of the mutation and copy-number data revealed three main pathways as frequently dysregulated in bladder cancer: cell cycle regulation (altered in 93% of cases); kinase and PI3K signaling (72%); chromatin remodeling, including mutations/SCNAs in histone modifying genes (89%); and components of the SWI/SNF nucleosome remodeling complex (64%) (Fig. 4a). To complement those results for well-defined pathways, we applied network analysis methods to examine other possible interactions between genes and pathways (Fig. 4b). In particular, we used the TieDIE algorithm to search for causal regulatory interactions within the PARADIGM network, which connects mutated genes to active transcriptional hubs^{31,32}. The analysis identified a sub-network linking mutated histone-modifying genes to a large array of activated transcription factors, suggesting potential far-reaching effects of histone modification on other pathways (Supplementary Fig.

S8.2.1), converging on MYC/MAX regulation. Both MYC and MAX showed similar levels of pathway activity, independent of mutations in chromatin genes, suggesting that mutations in histone-modifying genes provide just one mechanism for disruption of the MYC/MAX hub. In contrast, tumours with chromatin-related mutations showed differential activity of transcription factors *FOXA2* and *SP1*, implicating de-differentiation processes as a result of the mutations. Our network analysis also identified *HSP90AA1* as a critical signaling hub, suggesting that inhibitors of HSP90 may have therapeutic value in urothelial carcinoma. Although the linkages between mutations and transcriptional changes were statistically significant in terms of their proximity in the network (as determined by permutation tests; see Supplementary Fig. S8.2), further studies will be needed to assess the biological relevance of the findings.

Integrated analysis also identified mutations, copy number alterations or RNA expression changes affecting the PI3-kinase/AKT/mTOR pathway in 42% of the tumours (Fig. 5a). Included were activating point mutations in *PIK3CA* (17%; potentially responsive to PI3K inhibitors), mutation or deletion of *TSC1* or *TSC2* (9%; potentially responsive to mTOR inhibitors) and overexpression of *AKT3* (10%; potentially responsive to AKT inhibitors). We also observed mutations, genomic amplifications or gene fusions that affect the RTK/RAS pathway in 44% of the tumours (Fig. 5b). Included were events that can activate *FGFR3* (17%; potentially responsive to FGFR inhibitors or antibodies), amplification of *EGFR* (9%; potentially responsive to EGFR antibodies or inhibitors), mutations of *ERBB3* (6%; potentially sensitive to ERBB kinase inhibitors) and mutation or amplification of *ERBB2* (9%; potentially sensitive to ERBB2 kinase inhibitors or antibodies). *ERBB3* mutations in bladder cancer have been noted previously⁴, but statistically significant mutation of *ERBB2* in bladder cancer has not been reported. Both genes are potential therapeutic targets in other diseases³³⁻³⁵ (Fig. 5c). Interestingly, *ERBB2* alterations were approximately as frequent in this study as in TCGA breast cancers, but with fewer amplifications and more mutations (Fig. 5d)²⁴.

Discussion

This integrated study of 131 invasive urothelial bladder carcinomas provides numerous novel insights into disease biology and delineates multiple potential opportunities for therapeutic intervention. Treatment for muscle-invasive bladder cancer has not advanced beyond cisplatin-based combination chemotherapy and surgery in the past 30 years³⁶, and no new drugs for the disease have been approved in that time. Median survival for patients with recurrent or metastatic bladder cancer remains 14-15 months with cisplatin-based chemotherapy, and there is no widely recognized second-line therapy³⁷. With the exception of a single case report, there is also no known benefit from treatment with newer, targeted agents³⁸. Several of the genomic alterations identified in this study, particularly those involving the PI3-kinase/AKT/mTOR, CDKN2A/CDK4/CCND1 and RTK/RAS pathways, as well as *ERBB2* (Her-2), *ERBB3* and *FGFR3*, are amenable in principle to therapeutic targeting. Clinical trials based on patients with relevant druggable genomic alterations are warranted.

FGFR3 mutation is a common feature of low-grade non-invasive papillary urothelial bladder cancer, but it occurs at a much lower frequency in high-grade invasive bladder cancer. The cluster analysis in Figure 3 highlights multiple mechanisms of *FGFR3* activation, and its strong association with papillary morphology. The data presented here suggest a subset of muscle-invasive cancers that can potentially be targeted through *FGFR3*. Similarly, *ERBB2* amplification may be targetable by strategies used in breast cancer, by small-molecule tyrosine kinase inhibitors or by novel immunotherapeutic approaches (NCT01353222)³⁴. The data here provide further support for several ongoing *ERBB2*-targeted trials in bladder

cancer and further define the subpopulation of cancers suited to that approach. Finally, cluster III of the integrated expression profiling analysis reveals the existence of a urothelial carcinoma subtype with high cancer stem cell content (including KRT14/5), perhaps providing another avenue for therapeutic targeting.

The alterations identified in epigenetic pathways also suggest new possibilities for bladder cancer treatment. Ninety-nine (76%) of the tumours analyzed here had an inactivating mutation in one or more of the chromatin regulatory genes, and 53 (41%) had at least two such mutations. Overall, the bladder cancers showed a mutational spectrum highly enriched with mutations in chromatin regulatory genes (Supplementary Table S2.10). Further, integrated network analyses revealed a profound impact of those mutations on the activity levels of various transcription factors and pathways implicated in cancer. Recent development of drugs that bind competitively to acetyl-lysine recognition motifs (*i.e.*, bromodomains) might prove useful for treatment of the subset of bladder tumours that have abnormalities in chromatin-modifying enzymes³⁹. Our findings suggest that bladder cancer is a prime candidate for further exploration of that approach to therapy.

Methods Summary

Tumour and normal samples were obtained with institutional review board-approved consent and processed using a modified AllPrep kit (Qiagen) to obtain purified DNA and RNA. Quality-control analyses revealed only modest batch effects (Supplementary Text S13.1). The tumours were profiled using Affymetrix SNP 6.0 microarrays for SCNAs, low-pass WGS (HiSeq) for SCNAs and translocations, RNA-seq (HiSeq) for mRNA and miRNA expression, Illumina Infinium (HumanMethylation450) arrays for DNA methylation, HiSeq for exome sequencing and RPPA for protein expression and phosphorylation. Statistical analysis and biological interpretation of the data were spearheaded by the TCGA Genome Data Analysis Centers. Sequence files are in CGHub (<https://cghub.ucsc.edu/>). All other molecular, clinical and pathological data are available through the TCGA Data Portal (<https://tcga-data.nci.nih.gov/tcga/>). Data matrices, molecular analysis results and supporting information are at http://tcga-data.nci.nih.gov/docs/publications/bladder_2013/. The data can be explored through a compendium of Next-Generation Clustered Heat Maps (<http://bioinformatics.mdanderson.org/main/TCGA/Supplements/NGCHM-BLCA>), the cBio Cancer Genomics Portal (<http://cbioportal.org>), PARADIGM (<http://sysbio.soe.ucsc.edu/paradigm/tutorial/>), SpliceSeq (<http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview>), MBatch batch effects assessor (<http://bioinformatics.mdanderson.org/tcgaatcheffects>) and Regulome Explorer (<http://explorer.cancerregulome.org/>). Also see Supplementary Materials.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to all of the patients and families who contributed to this study, as well as Chris Gunter and LeeAnn Chastain for scientific editing and Julia Zhang and C. Ron Bouchard for extraordinary administrative support. This work was supported by the following grants from the United States National Institutes of Health: U54 HG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025. Additional personnel and funding sources are gratefully acknowledged in the Supplements.

Analysis Working Group

The University of Texas MD Anderson Cancer Center - John N. Weinstein^(1a, 1b), Rehan Akbani^(1a), Bradley M. Broom^(1a), Wenyi Wang^(1a), David McConkey⁽¹⁾, *Baylor College of Medicine* - Seth Lerner^(2, 3), Margaret Morgan^(3, 6), Chad J. Creighton⁽⁵⁾, Carolyn Smith⁽⁸⁾, *Broad Institute* - David J. Kwiatkowski^(9, 11, 67), Andrew D. Cherniack⁽⁹⁾, Jaegil Kim⁽⁹⁾, Chandra Sekhar Pedamallu^(9, 10), Michael S. Noble⁽⁹⁾, *Memorial Sloan-Kettering Cancer Center* - Hikmat A. Al-Ahmadie⁽²³⁾, Victor E. Reuter⁽²³⁾, Jonathan E. Rosenberg⁽²³⁾, Dean F. Bajorin⁽²³⁾, Bernard H. Bochner⁽²³⁾, David B. Solit⁽²³⁾, *Oregon Health and Science University, Department of Urology* - Theresa Koppie⁽²⁴⁾, *Weill Medical College of Cornell University* - Brian Robinson⁽³²⁾, *National Institute of Environmental Health Sciences* - Dmitry Gordenin⁽³³⁾, David Fargo⁽³³⁾, Leszek Klimczak⁽³³⁾, Steven Roberts⁽³³⁾, *Optimum Therapeutics LLC* - Jessie Au⁽³⁴⁾, *University of Southern California Epigenome Center* - Peter W. Laird⁽³⁵⁾, Toshinori Hinoue⁽³⁵⁾, *Computational Biology Center, Memorial Sloan-Kettering Cancer Center* - Nikolaus Schultz⁽³⁷⁾, Ricardo Ramirez⁽³⁷⁾, *UCSD Department of Pathology* - Donna Hansel⁽⁴⁰⁾, *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill* - Katherine A. Hoadley⁽⁴⁴⁾, William Y. Kim^(44, 49, 53), *Department of Genetics, University of North Carolina at Chapel Hill* - Jeffrey S. Damrauer^(44, 49), *The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University* - Stephen B. Baylin⁽⁵⁹⁾

Genome Sequencing Center

Broad Institute - David J. Kwiatkowski^(9, 11, 67), Stacey B. Gabriel⁽⁹⁾, Gad Getz⁽⁹⁾, Carrie Sougnez⁽⁹⁾, Kristian Cibulskis⁽⁹⁾, Lee Lichtenstein⁽⁹⁾, Andrey Sivachenko⁽⁹⁾, Chip Stewart⁽⁹⁾, Mike Lawrence⁽⁹⁾, Eric Lander⁽⁹⁾.

Genome Characterization Centers

Dan L. Duncan Cancer Center, Human Genome Sequencing Center, Baylor College of Medicine - Chad J. Creighton⁽⁵⁾, Lawrence Donehower^(5, 7), *Broad Institute* - Andrew D. Cherniack⁽⁹⁾, Jaegil Kim⁽⁹⁾, Scott L. Carter⁽⁹⁾, Gordon Saksena⁽⁹⁾, Steven E. Schumacher⁽⁹⁾, Samuel S. Freeman⁽⁹⁾, Joonil Jung⁽⁹⁾, Stacey B. Gabriel⁽⁹⁾, Gad Getz⁽⁹⁾, Carrie Sougnez⁽⁹⁾, Chandra Sekhar Pedamallu^(9, 10), Rameen Beroukhi^(9, 10), Ami S

^{1a}Dept. of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

^{1b}Dept. of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

¹The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

²Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030

⁵Dan L. Duncan Cancer Center, Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030

⁸Baylor College of Medicine, Houston, Texas 77030

¹¹Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115

⁶⁷Harvard Medical School, Boston, MA

²³Memorial Sloan-Kettering Cancer Center, New York, NY 10065

²⁴Oregon Health and Science University, Department of Urology, 3303 SW Bond Avenue, CHH10U, Portland, OR 97239

³²Weill Medical College of Cornell University, New York, NY 10065

³³National Institute of Environmental Health Sciences, Research Triangle Park, NC, 27709

³⁴Optimum Therapeutics LLC, 9363 Towne Centre Drive, San Diego, CA 92121

³⁵University of Southern California Epigenome Center, University of Southern California, Los Angeles, California 90033

³⁷Computational Biology Center, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065

⁴⁰UCSD Department of Pathology 9500 Gilman Drive La Jolla, CA 92093

⁴⁴Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁴⁹Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁵³Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁵⁹Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231

⁷Department of Molecular Virology and Microbiology, Baylor College of Medicine, 1 Baylor Plaza 77030

Bhatt^(9, 10), Trevor Pugh^(9, 10), Matthew Meyerson^(9, 10), Lynda Chin^(9, 65), *Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency* - Andrew J. Mungall⁽¹⁴⁾, A. Gordon Robertson⁽¹⁴⁾, Adrian Ally⁽¹⁴⁾, Miruna Balasundaram⁽¹⁴⁾, Yaron S.N. Butterfield⁽¹⁴⁾, Noreen Dhalla⁽¹⁴⁾, Carrie Hirst⁽¹⁴⁾, Robert A. Holt⁽¹⁴⁾, Steven J.M. Jones⁽¹⁴⁾, Darlene Lee⁽¹⁴⁾, Haiyan I. Li⁽¹⁴⁾, Marco A. Marra⁽¹⁴⁾, Michael Mayo⁽¹⁴⁾, Richard A. Moore⁽¹⁴⁾, Jacqueline E. Schein⁽¹⁴⁾, Payal Sipahimalani⁽¹⁴⁾, Angela Tam⁽¹⁴⁾, Nina Thiessen⁽¹⁴⁾, Tina Wong⁽¹⁴⁾, Natasja Wye⁽¹⁴⁾, Reanne Bowlby⁽¹⁴⁾, Eric Chuah⁽¹⁴⁾, Ranabir Guin⁽¹⁴⁾, Andy Chu⁽¹⁴⁾, *University of Southern California Epigenome Center* - Peter W. Laird⁽³⁵⁾, Toshinori Hinoue⁽³⁵⁾, Hui Shen⁽³⁵⁾, Moiz S. Bootwalla⁽³⁵⁾, Timothy Triche Jr⁽³⁵⁾, Phillip H. Lai⁽³⁵⁾, David J. Van Den Berg⁽³⁵⁾, Daniel J. Weisenberger⁽³⁵⁾, *UCSD Department of Pathology* - Donna Hansel⁽⁴⁰⁾, *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill* - Katherine A. Hoadley⁽⁴⁴⁾, Saianand Balu⁽⁴⁴⁾, Tom Bodenheimer⁽⁴⁴⁾, Jeffrey S. Damrauer^(44, 49), Alan P. Hoyle⁽⁴⁴⁾, Stuart R. Jefferys⁽⁴⁴⁾, Shaowu Meng⁽⁴⁴⁾, Lisle E. Mose⁽⁴⁴⁾, Janae V. Simons⁽⁴⁴⁾, Mathew G. Soloway⁽⁴⁴⁾, Junyuan Wu⁽⁴⁴⁾, William Y. Kim^(44, 49, 53), Joel S. Parker^(44, 49), D. Neil Hayes^(44, 60), *Research Computing Center, University of North Carolina at Chapel Hill* - Jeffrey Roach⁽⁴⁵⁾, *Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill* - Elizabeth Buda⁽⁴⁶⁾, *Department of Biology, University of North Carolina at Chapel Hill* - Corbin D. Jones^(46, 47), Piotr A. Mieczkowski⁽⁴⁷⁾, Donghui Tan⁽⁴⁷⁾, Umadevi Veluvolu⁽⁴⁷⁾, Scot Waring⁽⁴⁷⁾, Matthew D. Wilkerson⁽⁴⁷⁾, *Eshelman School of Pharmacy, University of North Carolina at Chapel Hill* - J.Todd Auman⁽⁴⁸⁾, *Department of Genetics, University of North Carolina at Chapel Hill* - Charles M. Perou⁽⁴⁹⁾, *Department of Genetics, Harvard Medical School* Netty Santoso⁽⁵⁵⁾, Jonathan Seidman⁽⁵⁵⁾, Michael Parfenov⁽⁵⁵⁾, Xiaojia Ren⁽⁵⁵⁾, Angela Hadjipanayis⁽⁵⁵⁾, Angeliki Pantazi⁽⁵⁵⁾, *The Center for Biomedical Informatics, Harvard Medical School* - Semin Lee⁽⁵⁶⁾, Lixing Yang⁽⁵⁶⁾, - Peter J. Park^(56, 58, 62), *Harvard Medical School-Partners Health Care Center for Genetics and Genomics* - Raju Kucherlapati⁽⁵⁷⁾, *Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University* - Stephen B. Baylin⁽⁵⁹⁾, *Division of Genetics, Brigham and Women's Hospital* - Andrew Wei Xu⁽⁶²⁾, *Institute for Applied Cancer Science, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center* - Alexei Protopopov⁽⁶⁵⁾, Jianhua Zhang⁽⁶⁵⁾, Christopher Bristow⁽⁶⁵⁾, Harshad S. Mahadeshwar⁽⁶⁵⁾, Sahil Seth⁽⁶⁵⁾, Xingzhi Song⁽⁶⁵⁾, Jiabin Tang⁽⁶⁵⁾, Dong Zeng⁽⁶⁵⁾, *The University of Texas MD Anderson Cancer Center, Department of Pathology* - Charles Guo⁽⁶⁶⁾

Genome Data Analysis Centers

The University of Texas M.D. Anderson Cancer Center - John N. Weinstein^(1a, 1b), Rehan Akbani^(1a), Bradley M. Broom^(1a), David McConkey⁽¹⁾, Tod D. Casasent^(11a), Yuexin

⁶⁵Inst. for Applied Cancer Science, Dept. of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA

¹⁴Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6

⁶⁰Department of Internal Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁴⁵Research Computing Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁴⁶Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁴⁷Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁴⁸Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 USA

⁵⁵Department of Genetics, Harvard Medical School, Boston, MA 02115 USA

⁵⁶The Center for Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA

⁵⁸Informatics Program, Children's Hospital, Boston, Massachusetts 02115, USA

⁶²Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA

⁵⁷Harvard Medical School-Partners HealthCare Center for Genetics and Genomics, Boston, MA 02115, USA.

⁶⁶The University of Texas MD Anderson Cancer Center, Department of Pathology, Unit 085; 1515 Holcombe Boulevard, Houston, TX 77030

Liu⁽¹⁾, Yiling Lu⁽¹⁾, Gordon B. Mills⁽¹⁾, Thomas Motter⁽¹⁾, Bo Peng^(11a), Michael Ryan^(11a), Wenyi Wang^(1a), Xiaoping Su^(11a), Ji-Yeon Yang^(11a), Hui Yao⁽¹⁾, Nianxiang Zhang^(11a), Jiexin Zhang^(11a), *Broad Institute* - Michael S. Noble⁽⁹⁾, Juok Cho⁽⁹⁾, Daniel DiCara⁽⁹⁾, Scott Frazer⁽⁹⁾, Nils Gehlenborg⁽⁹⁾, David I. Heiman⁽⁹⁾, Pei Lin⁽⁹⁾, Rileen Sinha⁽³⁷⁾, Carrie Sougnez⁽⁹⁾, Petar Stojanov^(9, 10), Doug Voet⁽⁹⁾, Hailei Zhang⁽⁹⁾, Lihua Zou⁽⁹⁾, Gad Getz⁽⁹⁾, Lynda Chin^(9, 65), Stacey B. Gabriel⁽⁹⁾, *Institute for Systems Biology* - Brady Bernard⁽¹²⁾, Dick Kreisberg⁽¹²⁾, Sheila Reynolds⁽¹²⁾, Hector Rovira⁽¹²⁾, Ilya Shmulevich⁽¹²⁾, *Computational Biology Center, Memorial Sloan-Kettering Cancer Center* - B. Arman Aksoy⁽³⁷⁾, Yevgeniy Antipin⁽³⁷⁾, Giovanni Ciriello⁽³⁷⁾, Gideon Dresdner⁽³⁷⁾, Jianjiong Gao⁽³⁷⁾, Benjamin Gross⁽³⁷⁾, Anders Jacobsen⁽³⁷⁾, Marc Ladanyi⁽³⁷⁾, William Lee⁽³⁷⁾, Ricardo Ramirez⁽³⁷⁾, Boris Reva⁽³⁷⁾, Chris Sander⁽³⁷⁾, Nikolaus Schultz⁽³⁷⁾, Ronglai Shen⁽³⁷⁾, Rileen Sinha⁽³⁷⁾, S. Onur Sumer⁽³⁷⁾, Nils Weinhold⁽³⁷⁾, *Buck Institute for Research on Aging* - Christopher Benz⁽³⁸⁾, *University of Calif. Santa Cruz* - Daniel Carlin⁽³⁹⁾, David Haussler⁽³⁹⁾, Sam Ng⁽³⁹⁾, Evan O. Paull⁽³⁹⁾, Joshua Stuart⁽³⁹⁾, Jing Zhu⁽³⁹⁾, *Department of Pathology, MD Anderson Cancer Center* - Wenbin Liu⁽⁶¹⁾, Wei Zhang⁽⁶¹⁾, *Helen Diller Family Comprehensive Cancer Center, University of California*, Barry S. Taylor⁽⁶⁴⁾

Biospecimen Core Resource

The Research Institute at Nationwide Children's Hospital - Tara M. Lichtenberg⁽⁴²⁾, Erik Zmuda⁽⁴²⁾, Thomas Barr⁽⁴²⁾, Aaron D. Black⁽⁴²⁾, Myra George⁽⁴²⁾, Benjamin Hanf⁽⁴²⁾, Carmen Helsel⁽⁴²⁾, Cynthia McAllister⁽⁴²⁾, Nilsa C. Ramirez⁽⁴²⁾, Teresa R. Tabler⁽⁴²⁾, Stephanie Weaver⁽⁴²⁾, Lisa Wise⁽⁴²⁾, Jay Bowen⁽⁴²⁾, Julie M. Gastier-Foster⁽⁴²⁾

Tissue Source Sites

The University of Texas M.D. Anderson Cancer Center - John N. Weinstein^(1a, 1b), Scott Department of Urology, Baylor College of Medicine - Seth Lerner^(2, 3), Weiguo Jian^(2, 3), Sebrina Tello^(2, 3), Texas Cancer Research Biobank (TCRB), Baylor College of Medicine - Michael Ittman^(3, 4), Patricia Castro^(3, 4), Whitney D. McClenden⁽³⁾, Margaret Morgan^(3, 6), Richard Gibbs^(3, 6), Broad Institute - Yingchun Liu⁽⁹⁾, Analytical Biological Services, Inc., - Charles Saller⁽¹³⁾, Katherine Tarvin⁽¹³⁾, Cleveland Clinic Foundation - Jennifer M. DiPiero⁽¹⁵⁾, Jennifer Owens⁽¹⁵⁾, Georgia Regents University Cancer Center - Roni Bollag⁽¹⁶⁾, Qiang Li⁽¹⁶⁾, Paul Weinberger⁽¹⁶⁾, Helen F. Graham Cancer Center at Christiana Care - Christine Czerwinski⁽¹⁷⁾, Lori Huelsenbeck-Dill⁽¹⁷⁾, Mary Iacocca⁽¹⁷⁾, Nicholas Petrelli⁽¹⁷⁾, Brenda Rabeno⁽¹⁷⁾, Pat Swanson⁽¹⁷⁾, International Genomics Consortium - Troy Shelton⁽¹⁸⁾, Erin Curley⁽¹⁸⁾, Johanna Gardner⁽¹⁸⁾, David Mallery⁽¹⁸⁾, Robert Penny⁽¹⁸⁾, ILSbio, LLC - Nguyen Van Bang^(19, 54), Phan Thi Hanh^(19, 54), Bernard Kohl⁽¹⁹⁾, Xuan Van Le⁽¹⁹⁾, Bui Duc Phu^(19, 54), Richard Thorp⁽¹⁹⁾, Nguyen Viet Tien^(19, 54), Le Quang Vinh^(19, 54), IU School of Medicine - George Sandusky⁽²⁰⁾, Lahey Hospital

¹²Institute for Systems Biology, 401 Terry Ave N, Seattle, WA, 98109

³⁸Buck Institute for Research on Aging; 8001 Redwood Blvd, Novato, CA 94945

³⁹Univ. Calif. Santa Cruz, 1156 High St., Santa Cruz, CA 95064

⁶¹Department of Pathology, MD Anderson Cancer Center, Houston, Texas 77030

⁶⁴Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158

⁴²The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205

⁴Department of Pathology, Baylor College of Medicine, Houston, Texas 77030

¹³Analytical Biological Services, Inc., 701 Cornell Drive, Wilmington, DE 19801

¹⁵Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, 44195

¹⁶Georgia Regents University Cancer Center. Augusta GA 30912

¹⁷Helen F. Graham Cancer Center at Christiana Care, 4701 oglestown stanton Rd, Newark, DE 19713

¹⁸International Genomics Consortium, 85340

¹⁹ILSbio, LLC 100 Radcliffe Drive, Chestertown, MD, 21620

⁵⁴Hue Central Hospital, Hue City, Vietnam

& Medical Center - Eric Burks⁽²¹⁾, Kimberly Christ⁽²¹⁾, Jason Gee⁽²¹⁾, Antonia Holway⁽²¹⁾, Alireza Moinzadeh⁽²¹⁾, Andrea Sorcini⁽²¹⁾, Travis Sullivan⁽²¹⁾, Memorial Sloan-Kettering Cancer Center - Hikmat A. Al-Ahmadie⁽²³⁾, Dean F. Bajorin⁽²³⁾, Bernard H. Bochner⁽²³⁾, Ilana Garcia-Grossman⁽²³⁾, Ashley Regazzi⁽²³⁾, David B. Solit⁽²³⁾, Jonathan E. Rosenberg⁽²³⁾, Victor E. Reuter⁽²³⁾, Oregon Health and Science University, Department of Urology - Theresa Koppie⁽²⁴⁾, University of North Carolina, Lineberger Cancer Center - Lori Boice⁽²⁵⁾, Wendy Kimryn Rathmell⁽²⁵⁾, Leigh Thorne⁽²⁵⁾, University of Pittsburgh - Sheldon Bastacky⁽²⁶⁾, Benjamin Davies⁽²⁶⁾, Rajiv Dhir⁽²⁶⁾, Jeffrey Gingrich⁽²⁶⁾, Ronald Hrebinko⁽²⁶⁾, Jodi Maranchie⁽²⁶⁾, Joel Nelson⁽²⁶⁾, Anil Parwani⁽²⁶⁾, Roswell Park Cancer Institute - Wiam Bshara⁽²⁷⁾, Carmelo Gaudioso⁽²⁷⁾, Carl Morrison⁽²⁷⁾, Ontario Tumour Bank - Hamilton site, St. Joseph's Healthcare Hamilton - Vina Alexopoulou⁽²⁸⁾, John Bartlett⁽²⁸⁾, Jay Engel⁽²⁸⁾, Sugy Kodeeswaran⁽²⁸⁾, The University of Chicago - Tatjana Antic⁽²⁹⁾, Peter H. O'Donnell⁽²⁹⁾, Norm D. Smith⁽²⁹⁾, Gary D. Steinberg⁽²⁹⁾, University of Miami, Sylvester Comprehensive Cancer Center - Sophie Egea⁽³⁰⁾, Carmen Gomez-Fernandez⁽³⁰⁾, Lynn Herbert⁽³⁰⁾, Merce Jorda⁽³⁰⁾, Mark Soloway⁽³⁰⁾, UT Southwestern Medical Center - Allison Beaver⁽³¹⁾, Suzie Carter⁽³¹⁾, Payal Kapur⁽³¹⁾, Cheryl Lewis⁽³¹⁾, Yair Lotan⁽³¹⁾, Weill Medical College of Cornell University - Brian Robinson⁽³²⁾, UCSD Department of Pathology - Donna Hansel⁽⁴⁰⁾, The University of Texas MD Anderson Cancer Center, Department of Pathology - Charles Guo⁽⁶⁶⁾, Jolanta Bondaruk⁽⁶⁶⁾, Bogdan Czerniak⁽⁶⁶⁾,

Disease working group

The University of Texas MD Anderson Cancer Center -, Rehan Akbani^(1a), Bradley M. Broom^(1a), John N. Weinstein^(1a, 1b), *Scott Department of Urology, Baylor College of Medicine -* Seth Lerner^(2, 3), *Broad Institute -* Jaegil Kim⁽⁹⁾, Andrew D. Cherniack⁽⁹⁾, Samuel S. Freeman⁽⁹⁾, Chandra Sekhar Pedamallu^(9, 10), Michael S. Noble⁽⁹⁾, David J. Kwiatkowski^(9, 11, 67), *Memorial Sloan-Kettering Cancer Center -* Hikmat A. Al-Ahmadie⁽²³⁾, Dean F. Bajorin⁽²³⁾, Bernard H. Bochner⁽²³⁾, David B. Solit⁽²³⁾, Jonathan E. Rosenberg⁽²³⁾, Victor E. Reuter⁽²³⁾, *Oregon Health and Science University, Department of Urology -* Theresa Koppie⁽²⁴⁾, *Weill Medical College of Cornell University -* Brian Robinson⁽³²⁾, *Stanford University, Department of Urology -* Eila Skinner⁽³⁶⁾, *Computational Biology Center, Memorial Sloan-Kettering Cancer Center -* Ricardo Ramirez⁽³⁷⁾, Nikolaus Schultz⁽³⁷⁾, *UCSD Department of Pathology -* Donna Hansel⁽⁴⁰⁾, *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill -* William Y. Kim^(44, 49, 53), *The University of Texas MD Anderson Cancer Center, Department of Pathology -* Charles Guo⁽⁶⁶⁾, Jolanta Bondaruk⁽⁶⁶⁾, Bogdan Czerniak⁽⁶⁶⁾,

Data Coordination Center

SRA International - Mark A. Jensen⁽⁴³⁾, Ari B. Kahn⁽⁴³⁾, Todd D. Pihl⁽⁴³⁾, David A. Pot⁽⁴³⁾, Deepak Srinivasan⁽⁴³⁾, Yunhu Wan⁽⁴³⁾,

²⁰IU School of Medicine, Med Science Bldg, Rm 128A, 635 Barnhill Drive, Indianapolis, In. 46202

²¹Lahey Hospital & Medical Center, Burlington, MA 01805

²⁵University of North Carolina, Lineberger Cancer Center, 450 West Drive, Chapel Hill, NC 27599

²⁶University of Pittsburgh, Pittsburgh PA 15213

²⁷Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo NY 14063

²⁸Ontario Tumour Bank - Hamilton site, St. Joseph's Healthcare Hamilton, Hamilton, Ontario L8N 3Z5, Canada

²⁹The University of Chicago, Chicago, IL 60637

³⁰University of Miami, Sylvester Comprehensive Cancer Center, 1550 NW 10th Avenue, Miami, FL 33136

³¹UT Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-9110

³⁶Stanford University, Department of Urology. 300 Pasteur Drive, Suite S287, Stanford, CA 94305

⁴³SRA International, Fairfax, Virginia 22033, USA

Project Team

MLF Consulting - Martin L. Ferguson⁽⁴¹⁾, *National Cancer Institute* - Jean Claude Zenklusen⁽⁵⁰⁾, Tanja Davidsen⁽⁵⁰⁾, John A. Demchok⁽⁵⁰⁾, Kenna R. Mills Shaw^(1, 50), Margi Sheth⁽⁵⁰⁾, Roy Tarnuzzer⁽⁵⁰⁾, Zhining Wang⁽⁵⁰⁾, Liming Yang⁽⁵⁰⁾, *National Human Genome Research Institute* - Carolyn Hutter⁽⁵¹⁾, Bradley A. Ozenberger⁽⁵¹⁾, Heidi J. Sofia⁽⁵¹⁾, *Scimentis, LLC*, - Greg Eley⁽⁵²⁾

References

1. Jemal A, et al. Global cancer statistics. *CA Cancer J Clin*. 2011; 61:69–90. [PubMed: 21296855]
2. Forbes SA, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res*. 2011; 39:D945–950. [PubMed: 20952405]
3. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. *Urol Oncol*. 2010; 28:409–428. [PubMed: 20610279]
4. Gui Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. *Nat Genet*. 2011; 43:875–878. [PubMed: 21822268]
5. Hurst CD, Platt FM, Taylor CF, Knowles MA. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. *Clin Cancer Res*. 2012; 18:5865–5877. [PubMed: 22932667]
6. Lindgren D, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. *PLoS One*. 2012; 7:e38863. [PubMed: 22685613]
7. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. *Hum Mol Genet*. 2013; 22:795–803. [PubMed: 23175443]
8. Wu YM, et al. Identification of Targetable FGFR Gene Fusions in Diverse Cancers. *Cancer Discov*. 2013
9. Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. 2013; 499:214–218. [PubMed: 23770567]
10. Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol*. 2013; 31:213–219. [PubMed: 23396013]
11. Lawrence M. MutSig. *Science*. 2013 in press.
12. Warfel NA, El-Deiry WS. p21WAF1 and tumorigenesis: 20 years after. *Curr Opin Oncol*. 2013; 25:52–58. [PubMed: 23159848]
13. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. *Genes Dev*. 2001; 15:15–23. [PubMed: 11156600]
14. Tontonoz P, et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. *Nucleic Acids Res*. 1994; 22:5628–5634. [PubMed: 7838715]
15. Shibata T, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. *Proc Natl Acad Sci U S A*. 2008; 105:13568–13573. [PubMed: 18757741]
16. Zhou J, Yu Q, Chng WJ. TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. *Int J Biochem Cell Biol*. 2011; 43:1668–1673. [PubMed: 21964212]
17. Solomon DA, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. *Science*. 2011; 333:1039–1043. [PubMed: 21852505]
18. Samowitz WS, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. *Journal of the National Cancer Institute*. 2006; 98:1731–1738. [PubMed: 17148775]

⁴¹MLF Consulting, Arlington, MA 02474 USA

⁵⁰National Cancer Institute, 31 Center Dr, 3A20, Bethesda, MD 20892

⁵¹National Human Genome Research Institute

⁵²Scimentis, LLC, Atlanta, GA30666 USA

19. Nik-Zainal S, et al. Mutational processes molding the genomes of 21 breast cancers. *Cell*. 2012; 149:979–993. [PubMed: 22608084]
20. Roberts SA, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. *Mol Cell*. 2012; 46:424–435. [PubMed: 22607975]
21. Singh D, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. *Science*. 2012; 337:1231–1235. [PubMed: 22837387]
22. Oneyama C, et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. *Oncogene*. 2011; 30:3489–3501. [PubMed: 21383697]
23. Yoshino H, et al. Aberrant expression of microRNAs in bladder cancer. *Nature reviews Urology*. 2013
24. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012; 490:61–70. [PubMed: 23000897]
25. Network, T. C. G. A. R. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 2012; 489:519–525. [PubMed: 22960745]
26. Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: getting to the root of the problem. *Nat Rev Urol*. 2012; 9:583–594. [PubMed: 22890301]
27. Sjodahl G, et al. A molecular taxonomy for urothelial carcinoma. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2012; 18:3377–3386. [PubMed: 22553347]
28. Korpai M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. *J Biol Chem*. 2008; 283:14910–14914. [PubMed: 18411277]
29. Ryan MC, Cleland J, Kim R, Wong WC, Weinstein JN. SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. *Bioinformatics*. 2012; 28:2385–2387. [PubMed: 22820202]
30. Christofk HR, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature*. 2008; 452:230–233. [PubMed: 18337823]
31. Vaske CJ, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. *Bioinformatics*. 2010; 26:i237–245. [PubMed: 20529912]
32. Network, T. C. G. A. R. Comprehensive Molecular characterization of clear cell Renal cell Carcinoma. *Nature*. 2013 in press.
33. Bose R, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. *Cancer Discov*. 2013; 3:224–237. [PubMed: 23220880]
34. Greulich H, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. *Proc Natl Acad Sci U S A*. 2012; 109:14476–14481. [PubMed: 22908275]
35. Jaiswal BS, et al. Oncogenic ERBB3 Mutations in Human Cancers. *Cancer Cell*. 2013; 23:603–617. [PubMed: 23680147]
36. National Comprehensive Cancer Network, I. NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer. 2012 V.1.2012.
37. von der Maase H, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J Clin Oncol*. 2005; 23:4602–4608. [PubMed: 16034041]
38. Iyer G, et al. Genome sequencing identifies a basis for everolimus sensitivity. *Science*. 2012; 338:221. [PubMed: 22923433]
39. Filippakopoulos P, et al. Selective inhibition of BET bromodomains. *Nature*. 2010; 468:1067–1073. [PubMed: 20871596]




Figure 1. The genomic landscape of bladder cancer

a, Mutation rate and type, histologic subtype, smoking status, gender, tumour stage, and cluster type. **b**, Genes with statistically significant levels of mutation (MutSig, FDR < 0.1) and mutation types. **c**, Deletions and amplifications for genomic regions with statistically significant focal copy number changes (GISTIC2.0). CN refers to absolute copy number. Note that two amplification peaks (*) contain several genes, any of which could be the target, as opposed to the single gene listed here. **d**, RNA expression level expressed as fold change from the median (of all samples). RPKM values are shown for selected genes subject to mutation and/or focal copy number change. Tumour samples were grouped into three clusters (red, blue, and green) using consensus NMF clustering (see the main text and Supplementary Figure 2.1.2). Three samples with no copy number data and two samples with no mutations in the genes were not used in the clustering and are shown in gray.




Figure 2. Structural rearrangements and viral integration

a, FGFR3-TACC3 fusion in sample TCGA-CF-A3MH showing the breakpoints in the two genes, the breakpoint junction sequences and the predicted fusion protein. **b**, Rearrangement involving DIP2B and ERBB2 in TCGA-DK-A2I6. The ERBB2 gene has swapped its promoter with that of DIP2B, resulting in over-expression of ERBB2. **c**, Insertion of human papilloma virus 16 (HPV16) into the BCL2L1 gene on chromosome 20 in TCGA-GC-A3I6. The region of BCL2L1 into which the virus has integrated and the integration junction sequence are shown.




Figure 3. Expression characteristics of bladder cancer

Integrated analysis of mRNA, miRNA and protein data led to identification of distinct subsets of urothelial carcinoma. Data for mRNA, miRNA and protein were z-normalized, and samples were organized in the horizontal direction by mRNA clustering. **a.** Papillary histology, *FGFR3* alterations, *FGFR3* expression and reduced *FGFR3*-related miRNA expression are enriched in cluster I. **b.** Expression of epithelial lineage genes and stem/progenitor cytokeratins are generally high in cluster III, some of which express variant squamous histology. **c.** Luminal breast and urothelial differentiation factors are enriched in clusters I and II. **d.** *ERBB2* mutation and estrogen receptor beta (*ESR2*) expression are enriched in clusters I and II.




Figure 4. Altered pathways and networks in bladder cancer

a. Somatic mutations and copy number alterations (CNA) in components of the p53/Rb pathway, RTK/RAS/PI3K pathway, histone modification system and SWI/SNF complex. Red, activating genetic alterations; blue, inactivating genetic alterations. Percentages shown denote activation or inactivation of at least one allele. **b.** The network connecting mutated histone-modifying genes to transcription factors with differential activity (methodology and larger implicated network in Supplementary Fig. 8.2.1). Each gene is depicted as a multi-ring circle with various levels of data, plotted such that each 'spoke' in the ring represents a single patient sample (same sample ordering for all genes). 'PARADIGM' ring: bioinformatically inferred levels of gene activity (red, higher activity); 'Transcriptional Activity': mean mRNA levels of all of the targets of each transcription factor; 'Expression': mRNA levels relative to normal (red, high); 'Mutation in gene': somatic mutation; 'Mutation in histone modifier genes': somatic mutation in at least one such gene; 'IPL anti-correlation': genes with PARADIGM Integrated Pathway Levels (IPLs) inversely correlated with histone-gene mutation status. Gene-gene relationships inferred using public resources.




Figure 5. Potential targets in bladder cancer

a, Alterations in the PI3K/AKT/MTOR pathway are mutually exclusive. Tumour samples are shown in columns, genes in rows. Only samples with at least one alteration are shown. AKT3 shows elevated expression in 10% of samples, independent of copy-number (right panel). **b**, Receptor tyrosine kinases are altered, by any of several different mechanisms (amplification, mutation, and fusion), in 45% of samples. Only mutations that are recurrent in this data set or previously reported in COSMIC are shown. **c**, Recurrent mutations in ERBB2 and ERBB3. The mutations shown in black are either recurrent in the TCGA data set or are reported in COSMIC. Green: Receptor L domain; red: furin-like cysteine-rich region; blue: growth factor receptor domain IV; yellow: tyrosine kinase domain. **d**, ERBB2 amplifications and recurrent mutations in other projects profiled by TCGA. Missense mutations were counted in the following positions: G309, S310, L313, R678, T733, L755, V777, D769, V842, T862, R896, M916I. In-frame insertions were counted between amino acids 774 and 776. Only tumour types with an alteration frequency $\geq 2\%$ are shown.